Stock News•1 months ago
Heartflow Q2 Earnings Call Highlights
Heartflow (NASDAQ: HTFL) reported Q2 revenue of $64.1 million, up 48% year-over-year, driven by growth in Plaque Analysis, durable FFR-CT utilization, and CCTA market expansion.
MarketLens
Heartflow's Q1 2026 Beat: Is This the Turning Point for HTFL
4 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Category
You may also like
Stock News•1 months ago
ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case
ClearPoint Neuro's Q2 results were weak, with drug delivery disposables lagging and preclinical service delays cutting 2026 expectations. Regulatory clarity now makes a revenue inflection likely in 20...
Stock News•2 months ago
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Heartflow and Iovance Biotherapeutics are compared as healthcare investments for 2026. Heartflow holds 1,450+ accounts in AI diagnostics, while Iovance shows revenue growth from personalized TIL cance...
Breaking News
View All →Featured Articles
Top Headlines
Stock News•1 hour ago
$10,000 in Tesla When It Joined the S&P 500 Would Be About $15,700 Today. An Index Fund Would Have Done Better.
Stock News•4 hours ago
J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion
Stock News•5 hours ago
Google's Historic 396 MW Clean Energy Deal Just Changed the Game for 1 AI Power Play
Stock News•6 hours ago
Better AI Chip Stock: Broadcom vs. Nvidia
Stock News•6 hours ago